What are the treatments for essential thrombocythemia?

Blood is a red, opaque, viscous liquid that flows through human blood vessels and heart. Blood is composed of plasma and blood cells. Blood cells include red blood cells, white blood cells, and platelets. Platelets are mainly involved in hemostasis and thrombus formation. Blood stores human health information. Many diseases require blood tests. Some people find that the number of platelets increases significantly during the blood test. In clinical practice, this condition is usually called thrombocytosis. &nbsp.&nbsp. Primary thrombocythemia (ET) patients are more common in middle-aged and elderly people over 40 years old. It is a type of myeloproliferative disease. Megakaryocytes in the bone marrow of patients are abnormally proliferated, and the platelet count is significantly increased. And there is a tendency to spontaneous bleeding and thrombosis. More than half of the patients are accompanied by splenomegaly, pulmonary embolism and myocardial infarction, and cerebral infarction can be life-threatening. &nbsp.&nbsp.So how to treat thrombocytosis? Primary thrombocytosis, there is still no specific treatment drug or method, it is one of the clinically difficult diseases. The main purpose of treatment is to reduce the number of platelets, prognose the occurrence of thrombosis and bleeding, and reduce disease progression, which is symptomatic The treatment methods are as follows:&nbsp.&nbsp.1. Decreasing cell therapy: use myelosuppressive drugs, especially for patients with platelets higher than 1000, including drugs such as hydroxyurea and interferon. Compared with the simple down-cell effect of hydroxyurea, interferon can inhibit megakaryocyte production and shorten the life span of platelets, but both can relapse after stopping the drug. &nbsp.&nbsp.2. Platelet separation quickly reduces the number of platelets and improves symptoms. It is often used for gastrointestinal bleeding, pregnancy and childbirth, and before elective surgery. &nbsp.&nbsp.3. General treatment using dipyridamole, aspirin, and indomethacin can prevent platelet aggregation. Patients with thrombosis should use heparin or double coumarin anticoagulants. Spleen cutting is contraindicated. &nbsp.&nbsp.4. JAK2 inhibitor-Luctinib (Jegwei): Since 2005, acquired mutations and primary genes of JAK2V617F, CALR, JAK2 exon 12 and MPLW515L/K have been discovered successively The occurrence of thrombocythemia is closely related. The mutation of the above-mentioned genes activates its downstream signaling pathways to cause excessive platelet proliferation, resulting in a series of clinical manifestations such as thrombocytosis, bleeding, thrombosis, and splenomegaly. Regarding this discovery, the JAK2 kinase (JAK2V617F) inhibitor-Rucotinib (Jegwei) has been clinically used to treat patients with essential thrombocythemia with myelofibrosis. Luctinib (Jegwei) is the world’s first approved JAK inhibitor. Current studies believe that the inhibitor has good curative effects and is a specific therapeutic drug. It can not only control the number of platelets, but also delay bone marrow fibrosis, shrink the spleen, and improve physical symptoms (such as fatigue, anorexia, sweating, anxiety, etc.) ). Although Jegway cannot cure ET, with the development of science, it is believed that in the future, more and more specific targeted therapy drugs will be developed and may be put into clinical use.